Trial Profile
Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay immunosuppression in comparison to current standard immunosuppression (mycophenolate mofetil, tacrolimus and continued corticosteroids) in renal transplantation.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Mycophenolate mofetil; Sirolimus; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms UK ELiTE
- 22 Jul 2020 Status changed from completed to discontinued.
- 20 Jun 2017 New trial record